A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Platelet count ≥ 50,000 cells/mm3, independent of transfusions within 7 days of screening assessment; Hemoglobin ≥ 8 g/dL, unless due to disease involvement in which case ≥ 7 g/dL, independent of transfusions within 7 days of screening assessment; Absolute neutrophil count >1000 cells/mcL, independent of growth factor support within 7 days of screening assessment; Total bilirubin < 1.5 x upper normal institutional limits. In patients with Gilbert's disease total bilirubin up to 3x ULN will be allowed; AST(SGOT)/ALT(SGPT) < 3 x institutional upper limit of normal unless elevation is caused by liver involvement with WM in which case AST and ALT may be ≤ 5 x ULN; Creatinine within normal institutional limits OR Creatinine clearance >40 mL/min for patients with creatinine levels above institutional normal (by Cockcroft-Gault estimate or 12-24h creatinine clearance measurements); Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or (international normalized ratio (INR) not greater than 1.5 x ULN; QTcF ≤ 470 msec; LVEF > 40% in the 12 months prior to start of treatment; No ≥ Grade 3 NYHA functional classification system of heart failure; No unstable angina, acute coronary syndrome within 2 months, or myocardial infarction within 3 months prior to start of treatment; No uncontrolled or symptomatic arrhythmias